Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin - ScienceDirect
Large NOAC trial stopped early as primary endpoint was reached ahead of time - PACE-CME
Figure 2, COMPASS Design Schematic - Clinical Review Report: Rivaroxaban ( Xarelto) - NCBI Bookshelf
The COMPASS Trial – Carlsibicky Internal Medicine APPE Blog
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial | Journal of the American College of Cardiology
COMPASS | Xarelto Global
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial - ScienceDirect
COMPASS Trial: Absolute Risk Differences Over Time for Severe Bleeding... | Download Scientific Diagram
Eligibility for Low-Dose Rivaroxaban Based on the COMPASS Trial: Insights from the Veterans Affairs Healthcare System | SpringerLink
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease | NEJM
Study design of COMPASS. To assess the safety and efficacy of... | Download Scientific Diagram
COMPASS Trial Revisited: Weighing Rivaroxaban Secondary Prevention vs DAPT After PCI | tctmd.com
The COMPASS Trial | Circulation
COMPASS Trial: Incidence Rates of Different Categories of Major Bleeding | Download Scientific Diagram
Eikelboom Net Clinical Benefit Video | XARELTO® (rivaroxaban)
Stroke Outcomes in the COMPASS Trial | Circulation
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial - ScienceDirect
Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial - ScienceDirect
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial | Journal of the American College of Cardiology
COMPASS - Research Studies - PHRI - Population Health Research Institute of Canada
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial - The Lancet
Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios | SpringerLink
COMPASS - ASA + rivaroxaban (or riva alone) vs ASA alone in stable CVD — NERDCAT
